{"title":"辉瑞为VLST提供临床期癌症抗体","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i9.1807","DOIUrl":null,"url":null,"abstract":"Seattle-based biotech VLST has moved into oncology and the clinical development arena by licensing CP-870,893, an anti-CD40 monoclonal antibody, from Pfizer. The drug has completed five Phase I trials and VLST will be responsible for advancing it into Phase II development. As part of the deal, Pfizer has acquired a 5% equity stake in VLST and will retain co-exclusive rights to the drug in the oncology vaccine field. The agreement represents the latest example of Pfizer’s portfolio management strategy in oncology.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"44 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pfizer Out-Licenses Clinical-Stage Cancer Antibody to VLST\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i9.1807\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Seattle-based biotech VLST has moved into oncology and the clinical development arena by licensing CP-870,893, an anti-CD40 monoclonal antibody, from Pfizer. The drug has completed five Phase I trials and VLST will be responsible for advancing it into Phase II development. As part of the deal, Pfizer has acquired a 5% equity stake in VLST and will retain co-exclusive rights to the drug in the oncology vaccine field. The agreement represents the latest example of Pfizer’s portfolio management strategy in oncology.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"44 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i9.1807\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i9.1807","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pfizer Out-Licenses Clinical-Stage Cancer Antibody to VLST
Seattle-based biotech VLST has moved into oncology and the clinical development arena by licensing CP-870,893, an anti-CD40 monoclonal antibody, from Pfizer. The drug has completed five Phase I trials and VLST will be responsible for advancing it into Phase II development. As part of the deal, Pfizer has acquired a 5% equity stake in VLST and will retain co-exclusive rights to the drug in the oncology vaccine field. The agreement represents the latest example of Pfizer’s portfolio management strategy in oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
